"The Bethesda system for reporting thyroid cytopathology comprises six categories of thyroid FNA reporting, with each category linked to a malignancy risk."
"usual management: repeat US-guided thyroid FNA (which will be diagnostic in ~70% (range 60-80%) of cases)"
"usual management: repeat US-guided thyroid FNA (which will be diagnostic in ~70% (range 60-80%) of cases)"
"atypia of undetermined significance; specify AUS-nuclear atypia or AUS-other"
"atypia of undetermined significance; specify AUS-nuclear atypia or AUS-other"
"usual management: repeat US-guided FNA, molecular testing (if available), diagnostic hemithyroidectomy, or surveillance"
"usual management: repeat US-guided FNA, molecular testing (if available), diagnostic hemithyroidectomy, or surveillance"
"In the first two editions, category III was called atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS), with the two terms considered synonymous 6,7. The third (2023) edition retired "follicular lesion of undetermined significance", retaining only "atypia of undetermined significance" 3."
"In the first two editions, category III was called atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS), with the two terms considered synonymous 6,7. The third (2023) edition retired "follicular lesion of undetermined significance", retaining only "atypia of undetermined significance" 3."
"ultrasound-guided FNA of the thyroid"
"McGill thyroid nodule score"
"Bethesda criteria of hereditary non-polyposis colorectal cancer"
"atypia of undetermined significance; specify AUS-nuclear atypia or AUS-other"
"follicular neoplasm; specify if oncocytic (Hürthle cell) type"
"suspicious for malignancy (e.g. papillary thyroid carcinoma, medullary thyroid carcinoma, metastatic carcinoma, lymphoma)"